KOL Market Snapshot Reports

Showing all 4 results

Get the latest industry data to drive your clinical and commercial decisions

Would you like to stay at the forefront of predicting the future of the oncology market and advancements in research and treatment? 

Do you find it too expensive to conduct market research studies with KOLs? 

Are you concerned you aren’t getting insights from the most relevant, globally-recognized key opinion leaders? 

Do you have a way to stay up to speed on the impact of all the latest clinical data releases throughout the year? 

Do you wish you didn’t have to pull together so many different sources of information to get a clear picture? 

Welcome to Cadence Communications & Research, a leader in market research and medical communications services for the healthcare industry for over 15 years. Our Market Snapshot reports provide meaningful and actionable insights on the current market trends, challenges and opportunities in oncology. Our current reports are delivered quickly after key conferences to provide the most up-to-date data releases so you can make informed clinical and commercial decisions. 

These reports are written for marketers, market researchers, C-suite executives, investors and hospital system administrators to better understand the current dynamics and future trends in the market, based on the perspective of highly respected KOLs.  

These focused reports are based on in-depth interviews with key opinion leading physicians from renowned, academic, medical centers in the United States, Europe, and Asia-Pacific. While we can’t ethically share our respondent list, these KOLs are the ones we know all our clients most want to hear from. Due to our long-standing work with oncology KOL’s worldwide, our access to them is top notch.  Our latest report had our expert respondents have an average of 125 co-authored clinical trial publications on late-stage prostate cancer, 8 out of 11 respondents chair or participate in guideline or peer-reviewed prostate cancer committees, and an average of 34 years of experience treating patients with prostate cancer.  Our current report includes: 

Current Prescribing Behavior 

  • What are the preferred treatment regimens in metastatic castration-resistant prostate cancer (mCRPC), high-risk non-metastatic castration-resistant prostate cancer (nmCRPC), and metastatic castration-sensitive prostate cancer (mCSPC) 
  • What determines the sequence of treatment options in mCRPC 
  • How PARP inhibitor studies in combination with androgen receptor pathway inhibitors will impact treatment decisions in 1st line, unselected mCRPC patients
  • How androgen receptor pathway inhibitors have impacted prescribing in mCSPC 
  • How the role of docetaxel will evolve in mCSPC 
  • Which androgen receptor pathway inhibitor is best-in-class and KOLs’ thoughts on each drug

Future Direction 

  • Which drugs, new classes of drugs have the potential to be approved in mCSPC, nmCRPC and mCRPC in the next year and over the next 2 – 5 years 
  • How the high-risk, nmCRPC market will evolve with the increased adoption of newer technologies
  • How Pluvicto and other radioligand programs are expected to be used in the future in prostate cancer 

Precision Medicine 

  • What is the short list of biomarkers KOLs believe should be used to determine treatment selection today 
  • How precision medicine may impact the overall landscape and treatment selection in advanced prostate cancer over the next 5 years
  • How KOLs see the treatment landscape evolving with the increasing use of PSMA PET and the impact on treatment across prostate cancer 

Evaluation of Efficacy Endpoints 

  • How regulatory agencies are thinking about primary endpoints in localized, locally advanced and metastatic prostate cancer 
  • How other endpoints, beyond overall survival, are impacting approvals and adoption in prostate cancer 

Cadence Market Snapshot Reports are delivered as a concise PowerPoint presentation. The aim is to deliver an impactful yet succinct deliverable that effectively communicates the key learnings from our interviews with market experts at far less cost than a traditional market research study. These findings will provide you with valuable insight to support your product decisions.  

Your feedback is appreciated. Contact Emily Anderson eanderson@cadenceresearch.com for questions.   

 To get a preview copy of the report CLICK HERE. 

 “Highly recommend this report for those interested in understanding current and future developments in Prostate Cancer. The report’s depth and coverage are impressive and the Cheat Code is helpful in quickly gaining the key insights.” 

– Marketing Executive, Pharmaceutical Company 

  • Sale!

    Prostate Cancer KOL Snapshot Report: April 2023

  • Non-Small Cell Lung Cancer KOL Snapshot Report: Coming Soon

  • Multiple Myeloma KOL Snapshot Report: Coming Soon

  • Breast Cancer KOL Snapshot Report: Coming Soon